Abound Wealth Management’s Genmab GMAB Stock Holding History

Abound Wealth Management’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$110	Sell	4 -3	-43%	-$80	﹤0.01%	1265
2026 Q1	$188	Hold	7	–	–	﹤0.01%	1253
2025 Q4	$216	Hold	7	–	–	﹤0.01%	1154
2025 Q3	$215	Hold	7	–	–	﹤0.01%	1094
2025 Q2	$145	Hold	7	–	–	﹤0.01%	1145
2025 Q1	$138	Sell	7 -1	-13%	-$21	﹤0.01%	1133
2024 Q4	$167	Hold	8	–	–	﹤0.01%	1144
2024 Q3	$196	Sell	8 -4	-33%	-$107	﹤0.01%	1175
2024 Q2	$302	Hold	12	–	–	﹤0.01%	981
2024 Q1	$359	Hold	12	–	–	﹤0.01%	1048
2023 Q4	$383	Buy	12 +3	+33%	+$94	﹤0.01%	1041
2023 Q3	$318	Hold	9	–	–	﹤0.01%	991
2023 Q2	$343	Buy	+9	New	+$359	﹤0.01%	996

Other funds holding GMAB

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Abound Wealth Management's GMAB Position: Q2 2026 in Review

Abound Wealth Management reduced its Genmab (GMAB) stake by 43% in Q2 2026, selling an estimated $80 and leaving 4 shares worth $110. The position accounts for ﹤0.01% of the portfolio, ranked #1265.

Abound Wealth Management first reported a position in GMAB in Q2 2023 and has held it in 13 quarters since. The position peaked at $383 in Q4 2023. 290 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

Abound Wealth Management held 4 shares of Genmab worth $110 as of Q2 2026.
Abound Wealth Management sold 3 Genmab shares in Q2 2026, an estimated $80.
Genmab made up ﹤0.01% of Abound Wealth Management's portfolio in Q2 2026, its #1265 holding.
Abound Wealth Management first reported a position in Genmab in Q2 2023 and has held it in 13 quarters since.
Abound Wealth Management's Genmab position peaked at $383 in Q4 2023.
290 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Abound Wealth Management's 13F filing for Q2 2026, filed 10 Jul 2026.